U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07049939) titled 'A Study of Bomedemstat (MK-3453) in Participants With Mild or Moderate Hepatic Impairment (MK-3453-023)' on June 25.
Brief Summary: The purpose of this study is to learn what happens to bomedemstat (MK-3453) in a person's body over time. Researchers will compare what happens to bomedemstat in the body when it is given to participants with mild or moderate hepatic (liver) impairment and healthy participants.
Participants will be allocated to one of three groups: mild hepatic impairment (HI), moderate HI, or healthy matched control. All participants will receive a single oral dose of bomedemstat on Day 1.
Healthy control participants...